A Newark federal court in the District of New Jersey has upheld
Pfizer's three main U.S. patents covering Celebrex, a selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. Generic manufacturer Teva Pharmaceuticals USA had challenged the patents.
Judge John C. Lifland ruled that the patents covering the active ingredient, pharmaceutical composition, and method of use for Celebrex are valid, enforceable and infringed by the generic manufacturer's product. The decision prohibits Teva from launching a competitor drug in the U.S. until December 2015. Teva Pharmaceuticals may appeal the decision.
Subscribe via RSS
